KDDD (Kyoto Drug Discovery and Development) is a spin-off company from Kyoto University. Our project is based on a result of research by Department of Ophthalmology Kyoto University and Graduate School of Biostudies. We sincerely aim to develop an innovative agent effective for various INCURABLE or INTRACTABLE eye diseases, especially CRAO, Retinal Pigmentosa, AMD and Glaucoma.
NUProtein develops next-generation protein and bioactive compound production technologies using genetically engineered rice. By cultivating high-expression rice and extracting target components directly from the grain, the company achieves exceptionally low-cost and stable production compared with conventional methods. NUProtein is also recognized as one of the world’s five industrial players in cell-free protein synthesis and gene-related patents. Through low-cost growth factors and other functional proteins, the company is building a new supply chain for the cultivated meat and broader food-tech sectors.
Integrated BioFoundry DBTL: BioFoundry (ultrahigh-speed microbial breeding) DBTL: Elementary technology utilization Scale-up process development In-house product development Intestinal microbiome model
We develop and sell therapeutic drugs and skin care cosmetics, focusing on drug transdermal absorption technology that can absorb both water-soluble and hydrophobic compounds of large molecular weight. In particular, in joint research with Kobe University, we found that carbon dioxide transdermal absorption has an increase and activation effect on mitochondria, and it has been revealed that it can safely increase muscle strength, promote healing of wounds/fractures, and inhibit scarring, partial weight loss by promoting fat metabolism, and induce apoptosis in cancer cells. Some products are on the market not only in Japan but also in other countries.
A Kyoto-based startup has developed the world's first cell therapy enabling nerve regeneration using ES/iPS cell-derived Schwann cells. This breakthrough enables large-scale production of cells previously difficult to mass-produce, paving the way for clinical trials.